Veracyte, Inc. is a genomic diagnostics company in the United States and internationally. The company is headquartered in South San Francisco, California.
| Revenue (TTM) | $561.90M |
| Gross Profit (TTM) | $414.44M |
| EBITDA | $113.52M |
| Operating Margin | 15.30% |
| Return on Equity | 8.77% |
| Return on Assets | 4.09% |
| Revenue/Share (TTM) | $7.08 |
| Book Value | $17.28 |
| Price-to-Book | 2.54 |
| Price-to-Sales (TTM) | 6.17 |
| EV/Revenue | 5.48 |
| EV/EBITDA | 22.51 |
| Quarterly Earnings Growth (YoY) | 288.90% |
| Quarterly Revenue Growth (YoY) | 15.50% |
| Shares Outstanding | $80.39M |
| Float | $79.88M |
| % Insiders | 0.49% |
| % Institutions | 114.80% |
Volatility is currently contracting
Milestone supports broader U.S. adoption of Prosigna and expands access for eligible patients with early-stage breast cancer Milestone supports broader U.S. adoption of Prosigna and expands access for eligible patients with early-stage breast cancer
SOUTH SAN FRANCISCO, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the third quarter 2026 after the close of market on Wednesday, November 4, 2026.
Six oral presentations and two posters will highlight Decipher's prognostic and predictive value in identifying patients' risk of progression and likelihood of benefiting from treatment intensification Six oral presentations and two posters will highlight Decipher's prognostic and predictive value in identifying patients' risk of progression and likelihood of benefiting from treatment intensification
Veracyte (VCYT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Veracyte, Inc. (VCYT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Acquisition positions Veracyte to deliver powerful genomic insights from urine, tissue, and blood to help guide bladder cancer care across the patient journey Acquisition positions Veracyte to deliver powerful genomic insights from urine, tissue, and blood to help guide bladder cancer care across the patient journey
GenAI offers growth potential for VCYT, GMED and UFPT, but regulatory and technology risks are likely to challenge adoption across healthcare.
SOUTH SAN FRANCISCO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced it will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026, at 7:00 a.m. Eastern Time.
VCYT's Afirma and Decipher sales momentum supports growth, while competition, macro pressures and rising investments remain key concerns.
Veracyte's 25.3% sell-off improves the entry price as strong core test demand and earnings growth face valuation, reimbursement and launch risks.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on VCYT and any ticker you trade — then tracks every position and per-strategy win rate.
